Cullinan Oncology, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| BIOIMPACT CAPITAL LLC | 11/13/2024 | 7.65 M | $128.03 M | 0.00% | 13.11% |
| BVF INC/IL | 11/14/2024 | 5.75 M | $96.27 M | 0.00% | 9.86% |
| BLACKROCK FUNDING, INC. /DE | 11/13/2024 | 4.34 M | $72.63 M | 100.00% | 7.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 11/14/2024 | 3.28 M | $54.91 M | -0.01% | 5.62% |
| VANGUARD GROUP INC | 11/13/2024 | 3.00 M | $50.20 M | 4.43% | 5.14% |
| STATE STREET CORP | 11/14/2024 | 2.34 M | $39.13 M | 20.40% | 4.01% |
| PARADIGM BIOCAPITAL ADVISORS LP | 11/14/2024 | 2.32 M | $38.85 M | 50.44% | 3.98% |
| FRANKLIN RESOURCES INC | 11/27/2024 | 2.19 M | $35.56 M | -10.35% | 3.76% |
| BLUE OWL CAPITAL HOLDINGS LP | 11/14/2024 | 2.01 M | $33.66 M | -1.86% | 3.45% |
| CITADEL ADVISORS LLC | 11/14/2024 | 1.96 M | $32.73 M | 0.62% | 3.35% |
| ALLIANCEBERNSTEIN L.P. | 11/14/2024 | 1.85 M | $31.04 M | 7.28% | 3.18% |
| RTW INVESTMENTS, LP | 11/14/2024 | 1.71 M | $28.56 M | 62.07% | 2.92% |
| HOLOCENE ADVISORS, LP | 11/14/2024 | 1.53 M | $25.67 M | 16.53% | 2.63% |
| VR ADVISER, LLC | 11/14/2024 | 1.38 M | $23.10 M | 0.00% | 2.37% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 11/14/2024 | 1.36 M | $22.70 M | -39.28% | 2.32% |
| SIREN, L.L.C. | 11/13/2024 | 1.21 M | $20.28 B | 100.00% | 2.08% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 1.21 M | $20.23 M | 23.75% | 2.07% |
| BRAIDWELL LP | 11/14/2024 | 1.18 M | $19.69 M | 567.62% | 2.02% |
| NEXTECH INVEST LTD. | 11/14/2024 | 1.14 M | $19.10 M | -6.55% | 1.96% |
| ORBIMED ADVISORS LLC | 11/14/2024 | 1.07 M | $17.91 M | -6.76% | 1.83% |
| MARSHALL WACE, LLP | 11/14/2024 | 1.05 M | $17.64 M | -11.00% | 1.81% |
| DIMENSIONAL FUND ADVISORS LP | 11/07/2024 | 1.02 M | $17.13 M | 34.64% | 1.75% |
| TANG CAPITAL MANAGEMENT LLC | 11/14/2024 | 921,138 | $15.42 M | 0.00% | 1.58% |
| BOXER CAPITAL, LLC | 11/14/2024 | 907,895 | $15.20 M | 38.00% | 1.56% |
| PATIENT SQUARE CAPITAL LP | 11/14/2024 | 824,705 | $13.81 M | 100.00% | 1.41% |
| MILLENNIUM MANAGEMENT LLC | 11/14/2024 | 788,567 | $13.20 M | 100.00% | 1.35% |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 11/14/2024 | 736,914 | $12.34 M | 11.94% | 1.26% |
| GOLDMAN SACHS GROUP INC | 11/14/2024 | 700,552 | $11.73 M | 54.72% | 1.20% |
| MORGAN STANLEY | 11/14/2024 | 673,372 | $11.27 M | -19.67% | 1.15% |
| FORESITE CAPITAL MANAGEMENT V, LLC | 11/14/2024 | 657,905 | $11.01 M | 0.00% | 1.13% |
| TWIN FOCUS CAPITAL PARTNERS, LLC | 11/14/2024 | 595,489 | $9.97 M | 0.00% | 1.02% |
| JANE STREET GROUP, LLC | 11/15/2024 | 489,100 | $8.19 M | 100.00% | 0.84% |
| AVIDITY PARTNERS MANAGEMENT LP | 11/14/2024 | 425,000 | $7.11 M | -72.75% | 0.73% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11/12/2024 | 423,959 | $7.10 M | 14.39% | 0.73% |
| AMERIPRISE FINANCIAL INC | 11/14/2024 | 417,508 | $6.99 M | 3.37% | 0.72% |
| LYNX1 CAPITAL MANAGEMENT LP | 11/14/2024 | 410,830 | $6.88 B | 8.88% | 0.70% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 409,793 | $6.86 M | -0.72% | 0.70% |
| WALLEYE CAPITAL LLC | 11/14/2024 | 328,417 | $5.50 M | 253.63% | 0.56% |
| CENTERBOOK PARTNERS LP | 11/14/2024 | 298,666 | $5.00 M | -12.48% | 0.51% |
| RENAISSANCE TECHNOLOGIES LLC | 11/13/2024 | 281,800 | $4.72 M | -33.18% | 0.48% |
| AFFINITY ASSET ADVISORS, LLC | 11/13/2024 | 263,817 | $4.42 M | 0.00% | 0.45% |
| BARCLAYS PLC | 11/19/2024 | 248,614 | $4.16 M | 26.00% | 0.43% |
| NUVEEN ASSET MANAGEMENT, LLC | 11/14/2024 | 233,566 | $3.91 M | 7.26% | 0.40% |
| SPHERA FUNDS MANAGEMENT LTD. | 11/14/2024 | 185,871 | $3.11 M | 100.00% | 0.32% |
| UBS GROUP AG | 11/14/2024 | 185,553 | $3.11 M | 15.99% | 0.32% |
| PFM HEALTH SCIENCES, LP | 11/14/2024 | 182,810 | $3.06 M | -38.25% | 0.31% |
| ENSIGN PEAK ADVISORS, INC | 11/14/2024 | 148,773 | $2.49 M | 0.00% | 0.26% |
| BANK OF NEW YORK MELLON CORP | 11/12/2024 | 138,346 | $2.32 M | 0.25% | 0.24% |
| ASSENAGON ASSET MANAGEMENT S.A. | 10/23/2024 | 135,036 | $2.26 M | 18.25% | 0.23% |
| RAFFERTY ASSET MANAGEMENT, LLC | 11/13/2024 | 114,670 | $1.92 M | 9.57% | 0.20% |
Cullinan Oncology, Inc.institutional Ownership - FAQ's
During the previous two years, 156 institutional investors and hedge funds held shares of Cullinan Oncology, Inc.. The most heavily invested institutionals were:
BioImpact Capital LLC: 7.65 M
BVF INC/IL: 5.75 M
BlackRock Funding, Inc. /DE: 4.34 M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C): 3.28 M
VANGUARD GROUP INC: 3 M
STATE STREET CORP: 2.34 M
111.43% of Cullinan Oncology, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 71.02 M shares in the last 24 months. This purchase volume represents approximately $823.80 M in transactions.